WallStreetZenWallStreetZen

NASDAQ: ENSC
Ensysce Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ENSC stock forecasts and price targets.

Forecast return on equity

Is ENSC forecast to generate an efficient return?

Company
N/A
Industry
80.44%
Market
61.97%

Forecast return on assets

Is ENSC forecast to generate an efficient return on assets?

Company
N/A
Industry
22.57%

ENSC earnings per share forecast

What is ENSC's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$9.77
Avg 2 year Forecast
$20.12

ENSC revenue forecast

What is ENSC's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$80.0M
Avg 2 year Forecast
$35.1M

ENSC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENSC$1.76N/AN/A
ONVO$1.72N/AN/A
CNSP$0.82N/AN/A
QLGN$3.24N/AN/A
THAR$1.13$17.00+1,404.42%Strong Buy
View Top Biotech Stocks

Ensysce Biosciences Stock Forecast FAQ

What is ENSC's earnings growth forecast for 2025-2026?

(NASDAQ: ENSC) Ensysce Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 18.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Ensysce Biosciences's earnings in 2025 is -$7,987,225.On average, 2 Wall Street analysts forecast ENSC's earnings for 2025 to be -$13,721,134, with the lowest ENSC earnings forecast at -$20,810,035, and the highest ENSC earnings forecast at -$6,632,232.

In 2026, ENSC is forecast to generate $28,264,270 in earnings, with the lowest earnings forecast at -$3,077,243 and the highest earnings forecast at $59,605,784.

If you're new to stock investing, here's how to buy Ensysce Biosciences stock.

What is ENSC's revenue growth forecast for 2026-2027?

(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Ensysce Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ENSC's revenue for 2026 to be $112,410,720, with the lowest ENSC revenue forecast at $112,410,720, and the highest ENSC revenue forecast at $112,410,720.

In 2027, ENSC is forecast to generate $49,348,306 in revenue, with the lowest revenue forecast at $49,348,306 and the highest revenue forecast at $49,348,306.

What is ENSC's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ENSC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 22.57%.

What is ENSC's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ENSC) Ensysce Biosciences's current Earnings Per Share (EPS) is -$11.45. On average, analysts forecast that ENSC's EPS will be -$9.77 for 2025, with the lowest EPS forecast at -$14.81, and the highest EPS forecast at -$4.72. In 2026, ENSC's EPS is forecast to hit $20.12 (min: -$2.19, max: $42.42).

What is ENSC's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ENSC) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.